Evidence map›Paper›PMID 34657986›Full record

ArticleNanoscale research letters2021

Preparation of ICA-loaded mPEG-ICA nanoparticles and their application in the treatment of LPS-induced H9c2 cell damage.

Lin Zhou, Zhi Huang, Shanyi Yang, Jiarui Wei, Yan Xu, Lin Hu, Xinrong Guo, Limin Yuan, Zexuan Yuan, Xiaoping Yang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanoscale research letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Lin Zhou *Department of Geriatrics and General Medicine (QZ) of Affiliated Taihe Hospital, Pharmaology Department (LZ, JW, XG, QZ), School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Zhi Huang *Key Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province (ZH, SY, YX, LY, ZY, XY, XT), School of Medicine, Hunan Normal University, Changsha, China.
Shanyi YangKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province (ZH, SY, YX, LY, ZY, XY, XT), School of Medicine, Hunan Normal University, Changsha, China.
Jiarui WeiDepartment of Geriatrics and General Medicine (QZ) of Affiliated Taihe Hospital, Pharmaology Department (LZ, JW, XG, QZ), School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Yan XuKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province (ZH, SY, YX, LY, ZY, XY, XT), School of Medicine, Hunan Normal University, Changsha, China.
Lin HuDepartment of Geriatrics and General Medicine (QZ) of Affiliated Taihe Hospital, Pharmaology Department (LZ, JW, XG, QZ), School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Xinrong GuoDepartment of Geriatrics and General Medicine (QZ) of Affiliated Taihe Hospital, Pharmaology Department (LZ, JW, XG, QZ), School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Limin YuanKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province (ZH, SY, YX, LY, ZY, XY, XT), School of Medicine, Hunan Normal University, Changsha, China.
Zexuan YuanKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province (ZH, SY, YX, LY, ZY, XY, XT), School of Medicine, Hunan Normal University, Changsha, China.
Xiaoping YangKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province (ZH, SY, YX, LY, ZY, XY, XT), School of Medicine, Hunan Normal University, Changsha, China.
Xiaojun TaoKey Laboratory of Study and Discovery of Small Targeted Molecules of Hunan Province (ZH, SY, YX, LY, ZY, XY, XT), School of Medicine, Hunan Normal University, Changsha, China. xiaojtao@126.com.ORCID http://orcid.org/0000-0002-3451-9850
Qiufang ZhangDepartment of Geriatrics and General Medicine (QZ) of Affiliated Taihe Hospital, Pharmaology Department (LZ, JW, XG, QZ), School of Basic Medical Science, Hubei University of Medicine, Shiyan, 442000, Hubei, China. zqf112000@163.com.

Funding

hubei key laboratory of wudang local chinese medicine research WDCM2019001)Huxiang High-Level Talent Innovation Team 2018RS3072siyan science and technology bureau 2020K36The Open Project of Hunan Normal University Medical College KF2021004
6 · The paper itself

Abstract

Hydrophilic polyethylene glycol monomethyl ether (mPEG) was grafted onto Icariin (ICA) by succinic anhydride to form a polyethylene glycol-Icariin (mPEG-ICA) polymer. The structure of the polymer was characterized by Fourier transform infrared spectroscopy (FT-IR) and nuclear magnetic resonance spectroscopy (NMR). mPEG-ICA nanoparticles loaded with ICA were prepared by physical embedding of ICA by dialysis. The particle size was determined to be (220 ± 13.7) nm, and the ζ potential was (2.30 ± 1.33) mV by dynamic light scattering (DLS). Under a transmission electron microscope (TEM), the nanoparticles were spherical, and the morphology was regular. In the medium with pH 7.4, the drug release rate of mPEG-ICA nanoparticles reached (52.80 ± 1.70)% within 72 h. At pH 6.8, the cumulative drug release of nanoparticles reached (75.66 ± 0.17)% within 48 h. Treatment of the nanoparticles with LPS-treated H9c2 cells maintained cell viability, reduced LDH release and exerted antiapoptotic effects. Moreover, ICA-loaded mPEG-ICA nanoparticles significantly decreased the mRNA expression of the myocardial inflammatory cytokines TNF-α, IL-1β and IL-6M. In conclusion, ICA-loaded mPEG-ICA nanoparticles protected against LPS-induced H9c2 cell injury.

Indexed as

Dynamic light scattering (DLS)Fourier infrared spectroscopyIcariin (ICA)Nuclear magnetic resonance spectroscopy (NMR)Polyethylene glycol monomethyl ether (mPEG)

Identifiers

PMID34657986
PMCPMC8523016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.